Investors appear to reacting to its update on onvansertib. According to CEO Dr. Thomas Adams, the PLK1 inhibitor has shown activity (more specifics needed) in more than 88% of evaluable acute myeloid leukemia (AML) patients to date.
Enrollment in a Phase 1b/2 study in metastatic colorectal cancer (mCRC) should start mid-year.
Data readouts from a Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) should continue throughout the year.
Interim data from its Phase 1b/2 study in AML and Phase 2 trial in mCRPC will be presented in a few weeks at AACR in Atlanta.
On the working capital front, at the end of December 2018, it had $11.5M in cash and equivalents. Operations consumed $13.2M in cash for the year.
Subscribe for full text news in your inbox